Rivastigmine is used to treat the symptoms of dementia, such as memory loss.
The monthly rate of discontinuations due to adverse events with galantamine was comparable to the rate with placebo during the maintenance phase of the study, suggesting that the rapid, rigid dose escalation procedure may have contributed to patients discontinuing galantamine treatment.
Multiple metabolic pathways and renal excretion are involved in the elimination of galantamine so no single pathway appears predominant.
Therefore, the ability of patients with dementia on rivastigmine therapy to continue driving or operating complex machines should be routinely evaluated by the treating physician.
Galantamine is not recommended for people with severely reduced liver function.
In oral studies with male and female rats, no adverse effects of rivastigmine were observed on fertility or reproductive performance of either the parent generation or the offspring of the parents.
As a carbamate, rivastigmine binds to AChE which cleaves the rivastigmine molecule, releasing a phenolic cleavage product that is almost pharmacologically inert and is rapidly excreted via the kidneys.
In view of its pharmacodynamic effects and possible additive effects, rivastigmine should not be given concomitantly with other cholinomimetic substances.
The table below contains some of the most common ones associated with galantamine.
Caregivers and patients should be advised that cholinomimetics, including rivastigmine, may exacerbate or induce extrapyramidal symptoms.
Rivastigmine is a type of medicine called an acetylcholinesterase inhibitor.
At the end of the study period, NPI scores remained at baseline levels in patients who received rivastigmine for 96 weeks.